Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Urinary microbiome of men with and without prostate cancer

PROVIDER: PRJNA680348 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR13120000_1.fastq.gz	Fastqsanger.gz
	SRR13120000_2.fastq.gz	Fastqsanger.gz
	SRR13120100_1.fastq.gz	Fastqsanger.gz
	SRR13120100_2.fastq.gz	Fastqsanger.gz
	SRR13120001_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 258

Similar Datasets

Project description:Prostate cancer ：urinary microbiome

| PRJNA510509 | ENA

Prostate Cancer Field Effect

2010-10-18 | GSE24171 | GEO

Unravelling the proteomic landscape of extracellular vesicles in prostate cancer by density-based fractionation of urine

Project description:Mass spectrometry-based proteomic analysis of urinary EV (uEV) in men with benign and malignant prostate disease, profiling the proteome of EV separated from prostate tumor interstitial fluid and matched uEV, and a comparative proteomic analysis with uEV from patients with bladder and renal cancer.

2020-04-09 | PXD015289 | Pride

Prostate Cancer Field Effect

Project description:In this study, comparison of gene expression profiles in benign epithelia from men with prostate cancer to those of men without prostate cancer reveal differences in several genes associated with prostate cancer. Custom Agilent 44K whole human genome expression oligonucleotide microarrays were used to profile benign epithelium from prostate needle biopsies from 15 men with high grade(Gleason 8-10) prostate cancer and 14 age- and BMI-matched controls. All samples were laser-capture microdissected and total RNA isolated and amplified prior to hybridization against a common reference pool of prostate tumor cell lines

2010-10-18 | E-GEOD-24171 | biostudies-arrayexpress

Protein Signatures to Distinguish Aggressive from Indolent Prostate Cancer

Project description:We performed a mass spectrometry-based proteomic analysis of normal and malignant prostate tissues from 22 men who underwent surgery for prostate cancer. Prostate cancer samples included Grade Groups (3 to 5), with 8 patients experiencing recurrence and 14 without evidence of recurrence with a mean of 6.8 years of follow-up.

2022-05-04 | PXD028118 | Pride

Urinary endogenous peptides as biomarkers for prostate cancer

Project description:Prostate cancer (PCa) is one of the most prevalent cancer types in men worldwide. However, the main diagnostic tests available for PCa have limitations and need biopsy for histopathological confirmation of the disease. The prostate-specific antigen (PSA) is the main biomarker used for PCa early detection, but an elevated serum concentration is not cancer-specific. Therefore, there is a need for discovery of new non-invasive biomarkers that can accurately diagnose PCa. Here, we used trichloroacetic acid-induced protein precipitation and liquid chromatography-mass spectrometry to profile endogenous peptides in urine samples from patients with PCa (n = 33), benign prostatic hyperplasia (n = 25), and healthy individuals (n = 28). Receiver operating characteristic (ROC) curves were performed to evaluate the diagnostic performance of urinary peptides. In addition, proteasix tool was used for in silico prediction of protease cleavage sites. We found five urinary peptides derived from uromodulin significantly altered between the study groups, all of which were less abundant in the PCa group. In addition, urinary peptides outperformed PSA in discriminating between malignant and benign prostate conditions (AUC = 0.847), showing high sensitivity (81.82%) and specificity (88%). Overall, our study allowed the identification of urinary peptides with potential for use as non-invasive biomarkers in PCa diagnosis.

2022-10-25 | PXD037031 | Pride

Genome wide analysis of androgen-receptor binding sites and epigenetic condition in prostate cancer

Project description:Prostate cancer is the most common cancer in men and AR downstream signalings promote prostate cancer cell proliferation. To investigate the AR signaling, we performed ChIP sequence analysis in AR positive prostate cancer cell line, LNCaP. In addition, we used hormone-refractory prostate cancer model cells, Bicalutamide-resistant (BicR) to explore the differences of androgen signaling in prostate cancer progression. ChIP sequence analysis of AR binding sites and epigenetic condition in two prostate cancer cells

2015-09-01 | E-GEOD-66037 | biostudies-arrayexpress

Genome wide analysis of AR binding sites and histone modifications in prostate cancer

Project description:Prostate cancer is the most common cancer in men and AR downstream signalings promote prostate cancer cell proliferation.We performed ChIP-seq analysis to investigate the role of AR and histone modifications.In addition, by siRNA mediated knockdown of AR-associated factors, changes of AR-binding sites in prostate cancer cells were analyzed.. ChIP-sequence analysis of AR and its associated factors in prostate cancer cells

2015-02-08 | E-GEOD-62492 | biostudies-arrayexpress

gene profiles in prostate cancer and normal prostate tissues

Project description:Prostate cancer is one of the most commonly diagnosed cancers among men in the world and the pathogenesis of prostate cancer remains poorly understood. In this study, we intended to disclose genes that might be involved in tumorigenesis using cDNA microarray technology. Keywords: disease state analysis A total of 28 experiments were performed without replicates, using a pool of unrelated fetal tissues as common references. 25 experiments were done for prostate cancer versus common reference and 3 for normal prostate versus common reference. Prostate cancer and normal prostate samples were labeled with Cy5-dUTP. Common references were labeled with Cy3-dUTP.

2008-09-25 | E-GEOD-5957 | biostudies-arrayexpress

Project description:Comparison of the Urinary Microbiome in Men who have Sex with Men with and without Chlamydia trachomatis Infection

| PRJNA1089515 | ENA